No Data
No Data
GSK Cut to Neutral From Buy by UBS
GSK Cut to Neutral From Buy by UBS
UBS Downgrades GSK to Neutral
UBS analyst Jo Walton downgrades GSK (NYSE:GSK) from Buy to Neutral.
ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment
iTeos Therapeutics (ITOS) said Monday it has dosed the first patient in its phase 3 trial of belrestotug with dostarlimab, triggering a $35 million development milestone payment from its belrestotug p
ITeos Therapeutics Has Dosed First Patient In GALAXIES Lung-301 Phase 3 Trial Of Belrestotug+Dostarlimab Vs. Placebo+Pembrolizumab For First-line Advanced, Unresectable, Or Metastatic PD-L1 High Non-Small Cell Lung Cancer
This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug.iTeos and GSK entered into an exclusive development and commercialization collaboration in
GSK Says First Single-Dose Medicine To Prevent Relapse Of P. Vivax Malaria Launched In Thailand And Brazil
GSK Says First Single-Dose Medicine To Prevent Relapse Of P. Vivax Malaria Launched In Thailand And Brazil
What the U.K. Election Means for Oil Stocks and Other Sectors -- Barrons.com
By Brian Swint U.K. voters gave the biggest election victory to the Labour Party since former Prime Minister Tony Blair's landslide win in 1997. If history is anything to go by, that could be a boon